Pharmafile Logo
Pharmafocus logo
Advanced Search

Imfinzi

Showing 15 posts of 27 posts found.

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024
Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …

News

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …

News

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

November 13, 2023
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …

News
astrazeneca_plaque

AstraZeneca to withdraw Imfinzi US indication for bladder cancer

February 22, 2021
Sales and Marketing AstraZeneca, Imfinzi

AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option

January 15, 2021
Medical Communications AstraZeneca, Cancer, Imfinzi

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …

News
astrazeneca_building_white

EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer

December 15, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s …

News

AstraZeneca scores Japanese approval for Imfinzi combo in extensive-stage small cell lung cancer

August 21, 2020
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, Japan

AstraZeneca’s Imfinzi (durvalumab) has secured approval in Japan for the treatment of extensive-stage small cell lung cancer when combined with etoposide and …

News
astrazeneca_sign_sky

Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia

July 27, 2020
Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi

AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …

News
astrazeneca_building_white

FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer

March 30, 2020
Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma

AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …

News
astrazeneca_building_white

Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer

March 17, 2020
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma

AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …

News
az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

News
china-1081714_1920

China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer

December 12, 2019
Sales and Marketing AstraZeneca, Imfinzi, pharma

AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …

News

FDA gives priority review for AstraZeneca’s Imfinzi

November 29, 2019
Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer

The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …

News

AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

October 29, 2019
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …

News

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026